John G. Moffat

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations

Medicine, Cancer Biology, Oncology +16

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Anneleen Daemen, David Peterson, Nisebita Sahu et al. · Proceedings of the National Academy of Sciences · 2015 · 418 citations · Full text

Medicine, Biochemistry, Oncology +17

Ser ¹²⁹² Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

Zejuan Sheng, Shuo Zhang, Daisy Bustos et al. · Science Translational Medicine · 2012 · 375 citations

Medicine, Cell Biology, Pharmacology +10

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

Marie-Claire Wagle, Daniel C. Kirouac, Christiaan Klijn et al. · npj Precision Oncology · 2018 · 213 citations · Full text

Medicine, Cancer Biology, Oncology +17

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien et al. · Molecular Cancer Therapeutics · 2012 · 209 citations · Full text

Medicine, Oncology, Pharmacology +17